Background: Although axillary hyperhidrosis is readily treated with botulinum toxin, the time course of benefits is not well established.
Objective: To quantify the long-term effectiveness of botulinum toxin type A (BTX-A) for the treatment of axillary hyperhidrosis.
Methods: This was a double-blind, placebo-controlled study. Eighteen patients received intradermal injections of either 100 U BTX-A (50 U/ml/axilla) or placebo. Sweating per surface area was quantified monthly for 5 months.
Results: The BTX-A group had an average reduction in sweat production of 91.6% at 2 weeks (from 5.03 ml/min/m(2) to 0.42 ml/min/m(2), P <.05). The average reduction over 5 months was 88.2%. At the end of the study, only 1 of 12 BTX-A-treated patients had returned to baseline sweat production.
Conclusion: These quantitative results demonstrate that BTX-A is a safe and effective treatment for axillary hyperhidrosis and that the benefits last for at least 5 months.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1524-4725.2002.01252.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of botulinum toxin injection in the management of chronic symptomatic anal fissure: a systematic review and meta-analysis of randomized controlled trials.
Tech Coloproctol
January 2025
Royal Glamorgan Hospital, Llantrisant, Wales, UK.
Background: Anal fissure is one of the most painful anal conditions. Various management options are available, including topical nitrites, calcium channel blockers, botulinum toxin injection, and lateral internal sphincterotomy. This study aimed to assess the efficacy and safety of botulinum toxin A (BT) injection for the management of symptomatic chronic anal fissures by conducting a systematic review of the literature and meta-analysis of published randomized controlled trials (RCTs).
View Article and Find Full Text PDFThe effect of ultrasound-guided botulinum toxin injections on pain, functionality, spasticity, and range of motion in patients with post-stroke upper extremity spasticity.
Rehabilitacion (Madr)
January 2025
University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey.
Objective: Spasticity developing in the upper extremity in stroke patients causes disability by limiting movement and causing pain. This study investigates the effects of botulinum toxin injections on pain, functionality, spasticity, and range of motion in hemiplegic patients with post-stroke spasticity.
Materials And Methods: The study involved a double-blind, prospective, randomized controlled trial with thirty-one stroke patients aged 35-80 who developed upper extremity spasticity.
Botulinum toxin therapy in Parkinson disease-related lower limb dystonia. An 8 year retrospective review.
Clin Park Relat Disord
June 2024
New York Medical College, Valhalla, NY, USA.
Background: Lower extremity dystonia (LED) is a frequent complication of Parkinson disease (PD). Treatment with botulinum neurotoxinA (BoNTA) over 8 years was retrospectively reviewed.Cases14 patients with LED received an average of 3.
View Article and Find Full Text PDFIatrogenic Botulism After Cosmetic Use of Botulinum Toxin-A: A Case Series.
Clin Case Rep
January 2025
Toxicological Research Center, Excellence Center & Department of Clinical Toxicology, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.
Botulism symptoms after cosmetic botulinum toxin-A (BTX-A) injections happen very rarely, and it needs careful attention since it can be life-threatening. Hence, it is advised to meticulously check the technique, dose, and authenticity of the BTX-A before injections to reduce the adverse effects.
View Article and Find Full Text PDFA Review of Current Techniques in Lip Reposition Surgery for Treating Excessive Gingival Display.
Cureus
December 2024
General Dentistry, College of Dentistry, King Saud bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Excessive gingival display (EGD), commonly known as a gummy smile (GS), is a cosmetic concern that involves exposing a significant area of gum tissue during a smile, rendering it unaesthetic. Gingival exposure greater than 3 mm is deemed aesthetically displeasing and often necessitates treatment to mask the gummy smile. The causes of EGD are multifactorial, including altered passive eruption (APE), hypermobile upper lip (HUL), short lip length, increased vertical maxillary component, gingival hyperplasia, dentoalveolar extrusion, and more.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!